Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.